Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients

PURPOSE: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE induces objective response in up to 57% of pancreatic neuroendocrine neoplasms (panNENs). Therefore, PRRT may comprise a downstaging option for panNEN patients who are not eligible for upfront curative surgery or are at high...

Descripción completa

Detalles Bibliográficos
Autores principales: Minczeles, Noémie S., van Eijck, Casper H. J., van Gils, Marjon J., van Velthuysen, Marie-Louise F., Nieveen van Dijkum, Els J. M., Feelders, Richard A., de Herder, Wouter W., Brabander, Tessa, Hofland, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250460/
https://www.ncbi.nlm.nih.gov/pubmed/35230492
http://dx.doi.org/10.1007/s00259-022-05734-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250460/
https://www.ncbi.nlm.nih.gov/pubmed/35230492
http://dx.doi.org/10.1007/s00259-022-05734-8

Ejemplares similares